LENZ Therapeutics Inc (LENZ)
16.36
-0.17
(-1.03%)
USD |
NASDAQ |
May 17, 16:00
16.36
0.00 (0.00%)
After-Hours: 20:00
LENZ Therapeutics Research and Development Expense (Quarterly): 10.54M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 10.54M |
| December 31, 2023 | 19.54M |
| Date | Value |
|---|---|
| March 31, 2023 | 10.32M |
| December 31, 2022 | 7.63M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
7.63M
Minimum
Dec 2022
19.54M
Maximum
Dec 2023
12.01M
Average
10.43M
Median
Research and Development Expense (Quarterly) Benchmarks
| TruBridge Inc | 10.69M |
| PetMed Express Inc | -- |
| Streamline Health Solutions Inc | 1.394M |
| R1 RCM Inc | -- |
| MoonLake Immunotherapeutics | 13.01M |